Kintor Pharmaceutical shares soared 17.51%
Kintor Pharmaceutical shares soared 17.51%
Shares of the Chinese drug developer-- $KINTOR PHARMA-B(09939.HK)$ increased 17.51% to 25.50 as at 11:04 am.
中國藥品開發商的股票--$金達醫藥-B(09939.HK)$截至上午11：04，增長17.51%至25.50
Accomplish Kintor's First Sales Revenue RMB34.23M in 2021
2021年實現Kintor首個銷售收入3423萬元人民幣
• Upfront payment of out-licensing contract with Fosun Pharma in India and 28 African countries
·在印度和28個非洲國家預付與復星國際醫藥公司簽訂的外部許可合同
• Upfront payment of out-licensing contract with Etana in Indonesia
·預先支付與印度尼西亞Etana簽訂的外部許可合同
Pioneer of Chinese Innovative Drugs' Globalization
中國創新藥物全球化的先行者
• 3 phase III MRCTs were approved by various countries' administration (FDA included)
·3個第三階段MRCT得到了各國政府(包括FDA)的批准
• 4 drug candidates（proxalutamide, pyrilutamide, ALK-1 antibody, GT20029）have clinical trials carried out within and out of China.
·4種候選藥物(丙沙魯胺、吡魯胺、ALK-1抗體、GT20029)在中國境內外進行了臨牀試驗。
Kintor said before the start of trading that a clinical trial for its proxalutamide drug candidate had effectively reduced the risk of hospitalization and death in outpatients with mild-to-moderate cases of Covid-19, including patients with high-risk factors such as older age.
Kintor在開盤前表示，其候選丙沙魯胺藥物的臨牀試驗有效地降低了新冠肺炎輕中度病例(包括年齡等高危因素患者)門診患者的住院和死亡風險。
